These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 35675927)

  • 21. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
    Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
    JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated CD21
    Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
    J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.
    Di Fusco M; Marczell K; Deger KA; Moran MM; Wiemken TL; Cane A; de Boisvilliers S; Yang J; Vaghela S; Roiz J
    J Med Econ; 2022; 25(1):605-617. PubMed ID: 35574613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia.
    Alamer E; Alhazmi A; Qasir NA; Alamer R; Areeshi H; Gohal G; Qadri M; Hashem AM; Algaissi A
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835228
    [No Abstract]   [Full Text] [Related]  

  • 25. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
    Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
    JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data.
    Cari L; Fiore P; Naghavi Alhosseini M; Sava G; Nocentini G
    J Autoimmun; 2021 Aug; 122():102685. PubMed ID: 34174723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
    Yasmin F; Najeeb H; Naeem U; Moeed A; Atif AR; Asghar MS; Nimri N; Saleem M; Bandyopadhyay D; Krittanawong C; Fadelallah Eljack MM; Tahir MJ; Waqar F
    Immun Inflamm Dis; 2023 Mar; 11(3):e807. PubMed ID: 36988252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
    Gordon SF; Clothier HJ; Morgan H; Buttery JP; Phuong LK; Monagle P; Chunilal S; Wood EM; Tran H; Szer J; Crawford NW;
    Vaccine; 2021 Nov; 39(48):7052-7057. PubMed ID: 34756770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6-14 months follow-up.
    Karavani G; Chill HH; Meirman C; Gutman-Ido E; Herzberg S; Tzipora T; Imbar T; Ben-Meir A
    J Assist Reprod Genet; 2022 Oct; 39(10):2249-2254. PubMed ID: 36114906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
    Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
    Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
    Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
    AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
    Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
    Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor.
    Marinaki S; Kolovou K; Liapis G; Skalioti C; Tsiakas S; Boletis I
    Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia.
    Alharbi NK; Al-Tawfiq JA; Alghnam S; Alwehaibe A; Alasmari A; Alsagaby SA; Alsubaie F; Alshomrani M; Farahat FM; Bosaeed M; Alharbi A; Aldibasi O; Assiri AM
    J Infect Public Health; 2022 May; 15(5):573-577. PubMed ID: 35472755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study.
    Sing CW; Tang CTL; Chui CSL; Fan M; Lai FTT; Li X; Wan EYF; Wong CKH; Chan EWY; Hung IFN; Leung AY; Cheung CL; Wong ICK
    Am J Hematol; 2022 Apr; 97(4):470-480. PubMed ID: 35080247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aseptic meningitis after SARS-CoV-2 Pfizer/BioNTech vaccination.
    Dupon V; Arnaert S; Van Haute E; Vulsteke F; Diet G; De Schoenmakere G
    Acta Clin Belg; 2022 Dec; 77(6):976-979. PubMed ID: 34882515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.